Avalon GloboCare’s (ALBT) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of Avalon GloboCare (NASDAQ:ALBT) in a report issued on Friday,Weiss Ratings reports.

Separately, Wall Street Zen lowered Avalon GloboCare to a “strong sell” rating in a research note on Saturday, September 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Avalon GloboCare Stock Performance

Shares of ALBT opened at $2.22 on Friday. Avalon GloboCare has a 1 year low of $1.87 and a 1 year high of $11.66. The company’s 50 day simple moving average is $2.33 and its 200 day simple moving average is $2.84. The company has a market capitalization of $8.52 million, a price-to-earnings ratio of -0.11 and a beta of 0.03.

Avalon GloboCare (NASDAQ:ALBT) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share for the quarter. The business had revenue of $0.35 million during the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.